Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorDEBORDE, M.
dc.contributor.authorPEREYRE, S.
dc.contributor.authorPUGES, M.
dc.contributor.authorBEBEAR, C.
dc.contributor.authorDESCLAUX, A.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHESSAMFAR, Mojgan
dc.contributor.authorLE ROY, C.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLE MAREC, Fabien
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDABIS, Francois
dc.contributor.authorCAZANAVE, C.
dc.date.accessioned2020-06-17T09:27:51Z
dc.date.available2020-06-17T09:27:51Z
dc.date.issued2019-08
dc.identifier.issn1769-6690 (Electronic) 0399-077X (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/7969
dc.description.abstractEnOBJECTIVES: Limited data on Mycoplasma genitalium infection has been reported among PrEP users. The aim of this study was to estimate the prevalence and macrolide resistance of M. genitalium infection among enrollees in a French PrEP program. PATIENTS AND METHODS: M. genitalium infection screening was systematically and prospectively proposed to patients of the Bordeaux PrEP program (between January 2016 and February 2017). Macrolide resistance was evaluated in M. genitalium-positive patients. RESULTS: Among 89 clients, M. genitalium infection prevalence was 10% (mainly asymptomatic) with a high rate of macrolide resistance (58%). CONCLUSIONS: Because of a high level of macrolide resistance, a systematic search for M. genitalium macrolide resistance associated-mutations may be recommended in PrEP users before initiating the antibiotic therapy.
dc.language.isoENen_US
dc.subject.enCOREVIH
dc.subject.enMORPH3Eus
dc.subject.enFR
dc.title.enHigh prevalence of Mycoplasma genitalium infection and macrolide resistance in patients enrolled in HIV pre-exposure prophylaxis program
dc.title.alternativeMed Mal Infecten_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.medmal.2019.03.007en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30914213en_US
bordeaux.journalMedecine Et Maladies Infectieusesen_US
bordeaux.page347-349en_US
bordeaux.volume49en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue5en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Medecine%20Et%20Maladies%20Infectieuses&rft.date=2019-08&rft.volume=49&rft.issue=5&rft.spage=347-349&rft.epage=347-349&rft.eissn=1769-6690%20(Electronic)%200399-077X%20(Linking)&rft.issn=1769-6690%20(Electronic)%200399-077X%20(Linking)&rft.au=DEBORDE,%20M.&PEREYRE,%20S.&PUGES,%20M.&BEBEAR,%20C.&DESCLAUX,%20A.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée